The founding product was a band worn on the upper arm. The larger idea was a hospital with no walls. Current Health, born in Edinburgh as Snap40, wanted to catch deterioration in a patient's vital signs before the ordinary rhythm of observation did. A medical student, Chris McGhee, and an engineer, Stewart Whiting, started with sensors. Over the next decade, their company discovered that sensors were the least troublesome part of sending sick people home.
A patient outside a ward still needs a blood-pressure cuff that connects, a tablet that makes sense, a nurse who sees the alert, a physician who owns the decision, a courier who retrieves the kit and a record that lands in the right place inside the electronic health system. Current Health turned those loose parts into an enterprise platform and services business. Health systems use it for hospital-at-home programs. Oncology networks use it to supervise patients receiving CAR-T and bispecific therapies outside an inpatient bed. Life-sciences companies use it for remote data collection, research and support around advanced treatments.
The product is the choreography
Current Health's clinical dashboard brings continuous and intermittent vital signs, symptoms and patient-reported information into one view. Organizations configure alarm thresholds and escalation pathways. The software integrates with major EHRs, supports video communication and can coordinate a choice of monitoring devices. A 24/7 Clinical Command Center adds licensed virtual nurses who triage signals according to the customer's protocol. Professional-services teams help design and launch the program. For hospital-at-home, Cardinal Health's Velocare now handles last-mile delivery, installation and retrieval of kits.
That full stack is the point of difference. A hospital can buy devices from Masimo or Philips, remote-monitoring software from Huma, Doccla or Health Recovery Solutions, and clinical services elsewhere. It can also build internally. Current Health argues for one accountable layer across the episode. Its expertise sits between medical-device engineering and the boring, decisive work of clinical operations: who watches, who responds, which patients qualify, and how the economics survive.
A $400 million lesson in market timing
By 2019 the company had FDA clearance for its wearable and an $11.5 million Series A. The pandemic then pulled remote care years forward. Current Health helped monitor an international COVID-19 vaccine trial, built an in-house clinical monitoring team and raised a $43 million Series B in April 2021. Six months later, Best Buy agreed to acquire it. The cash outlay was approximately $400 million.
The marriage was easy to explain. Current Health had clinical technology; Best Buy had consumer reach, device logistics and technicians accustomed to making unfamiliar equipment work in homes. Geek Squad, but with escalation pathways. Best Buy could deliver and install the kit while Current Health connected the patient's data to a hospital. For a moment, “home as the center of health” looked less like a slogan than a distribution plan.
Capital to scale the integrated remote-care platform globally.
The disclosed approximate cash cost of the acquisition.
McGhee reacquired the company; the price stayed private.
What failed first was not the wearable. It was the assumption that the market would scale on the acquirer's timetable. Hospitals liked the clinical idea but faced thin operating margins, staffing constraints and uncertainty around how acute care at home would be reimbursed after emergency-era policy. Best Buy said its in-home health business was expanding more slowly than expected. The retailer recorded a $475 million goodwill impairment tied to Best Buy Health in fiscal 2025, then additional health-unit impairments as projections fell.
In June 2025, McGhee and management bought Current Health back. The price was not disclosed. The company's own account says it right-sized operations, reached sustainable unit economics and made advanced therapies its primary growth driver. That is the change of mind: not abandoning care at home, but choosing the episodes where care at home has a sharp economic reason to exist.
Why the second act starts with CAR-T
Advanced therapies are expensive, capacity-constrained and clinically intense. CAR-T can produce cytokine release syndrome and neurologic toxicity, requiring close observation after infusion. Traditionally, much of that observation consumed inpatient beds at a small number of specialist centers. Current Health's pitch is that standardized patient selection, continuous monitoring, virtual nursing and explicit escalation can move much of the episode outpatient without pretending the risk disappeared.
Sarah Cannon, HCA Healthcare's cancer institute, provides a useful public example. Working across multiple sites, its teams used Current Health for vital-sign monitoring, symptom assessment and around-the-clock review. Current Health reports that 90 percent of evaluated patients in a recent cohort were eligible for outpatient care, 1,200 bed days were saved among the first 100 patients, and 67 percent stayed home for at least 72 hours. Earlier published materials described more than 75 percent of CAR-T therapies moving outpatient.
The risk also has a clock. Research from Sarah Cannon and Current Health found 98 percent of cytokine release syndrome events and 96 percent of neurologic events occurred within the first 15 days in the patients studied. An earlier interim analysis suggested continuous signals could identify signs of cytokine release syndrome a median of about three hours before standard nursing care. This does not make an algorithm a doctor. It makes concentrated staffing and escalation easier to design.
Who pays, and what they are paying for
Current Health is a business-to-business company. Its customers are health systems, oncology and transplant networks, community specialty practices and drugmakers. The company does not publish a price list. The likely commercial bundle includes platform access, implementation, monitoring, clinical services, research support and operational logistics, priced through enterprise contracts rather than a consumer subscription.
For a hospital, the return can be bed capacity, fewer avoidable readmissions and a larger service area without another tower. Mass General Brigham's Home Hospital program grew 200 percent in 15 months across 72 communities; a 2025 case study credited the broader program with more than 25,000 bed days saved. For a drug company, the prize is treatment adoption beyond a handful of academic centers, plus real-world evidence. For patients, the benefit is simpler: less time sleeping under fluorescent lights, if home is clinically and socially appropriate.
The part worth stealing
Current Health's path offers a better template than “add AI to healthcare.” It began with an observable risk, accumulated the operational pieces around it and, after an expensive detour through a much larger ambition, narrowed toward clinical episodes with measurable scarcity and payment logic.
The copyable care-infrastructure playbook
- Start with one costly bottleneck, not a population-sized promise. A scarce oncology bed is easier to price than “better health.”
- Instrument the full workflow. The signal, the nurse, the escalation and the EHR entry belong in the same product map.
- Bundle the ugly operations. Connectivity checks, kit retrieval and after-hours coverage are features when failure is clinical.
- Concentrate around a defined risk window. Staffing becomes more defensible when the danger has known timing and thresholds.
- Publish outcomes procurement can repeat: bed days, length of stay, adherence, readmissions and time to detection.
There is restraint in the new positioning. Current Health still supports hospital-at-home, but the home page now leads with advanced therapies and complex care. Cardinal Health handles more of the delivery plumbing. The company supplies clinical and financial infrastructure rather than claiming every living room should become an ICU. It is a smaller story than the Best Buy version, which may be why it has a better chance of working.
When this model does not travel well
- Reimbursement is temporary, ambiguous or smaller than the clinical and logistics cost.
- No provider team owns alerts around the clock, or alarm volume overwhelms the people who do.
- The patient lacks reliable connectivity, a safe home, a capable caregiver or rapid transport back to acute care.
- The complication window is too unpredictable for protocols and remote signals to reduce risk.
- Patient volume is too low to support the nursing, equipment and retrieval network.
Current Health occupies an awkward, useful place in the market. It is too clinical to be ordinary telehealth, too service-heavy to be pure SaaS and too software-shaped to be a device company. That hybridity made the business attractive to a retailer with home-service ambitions. It also exposed the company to every slow-moving dependency in American healthcare.
The buyback does not erase the $400 million experiment. It clarifies it. Sensors can show that care is leaving the hospital; they cannot decide who gets paid when it does. Current Health's second act is built around situations where the answer is finally becoming specific.